As an optimist I am not interested in safe, incremental projects. I am interested in challenging, high-risk, high-impact research. The perseverance of Dr. Katalin Karikó’s breakthrough work on mRNA vaccines is an inspiration.
I have been passionate about stem cell research since my first project on human embryonic stem cell lines in medical school. As the lead scientist of the “Thymus Engineering and 22q11DS” project at Stanford from 2017 to 2021, I become fascinated by the thymus, the primary immune organ for T cell development. Regenerating thymic epithelial cells from iPSCs provides a tool for manufacturing naïve T cell in vitro and holds tremendously potential to revolutionize T cell immunotherapies. Prior to Stanford, I was a senior scientist in the iPSC technology group at iPierian Inc, a pioneering iPSC startup, acquired by Bristol-Myers Squibb.
I recently left Stanford and started Rattan Life Science with a goal of focusing on this high-risk project. Looking forward to continuing the work I started in academia in a fast-paced startup environment, expanding into commercial applications and therapies.
I am very excited to be at MBC BioLabs and meet the great community!